HOME > TRENDS
TRENDS
-
Teva JV Deal Marks Turning Point in Takeda’s Japanese Business
January 6, 2016
-
“Huge Seller” Re-Pricing Targeting Hep C Drugs Will Dampen Innovative Market
December 9, 2015
-
Peak Sales Forecast for New Drugs Listed in 2015 Exceeded 840 Billion Yen with Big Contribution from Hep C Treatments
December 7, 2015
-
AG Shares Reach 50-60% in 1 Year; Confidence in Quality Encourages Dominance Even without Market Lead
November 30, 2015
-
Full-Year Forecasts for Domestic Market Down vs Previous Year; Major Makers Struggling Even in Year without NHI Price Revision
November 11, 2015
-
Shift to Specialty - 5: Eisai, Ajinomoto Jump on Specialty Bandwagon to Seek Efficiency in GI Biz
October 30, 2015
-
Drug Makers’ Payments to Medical Institutions Dip for Second Year: Jiho Tally
September 15, 2015
-
Transformation of ARB Market Spurred by AGs, Power Map Changing Fast as Brand-Name Drugs Falter
September 4, 2015
-
Japan Drug Makers See Rising Overseas Sales Ratios in April-June
August 11, 2015
-
IFN-Free Drugs Upending Hepatitis C Market Landscape
July 17, 2015
-
3 Major Japan Makers Shed 1,300 Jobs amid Redundancy Programs
June 30, 2015
-
“80% Generic” Era Would Further Accelerate Contraction of Market for Long-Listed Drugs
June 29, 2015
-
Top-4 Japanese Drug Makers Report Widely Different Financial Results for FY2014
May 22, 2015
-
Will 5,000 Contract Sales Reps Be Just a Way Station for a Higher Goal Beyond?
April 24, 2015
-
Global Drug Sales Rose 8.8% to US$936.5 Billion in 2014: IMS Health
April 3, 2015
-
Development Tie-Ups with Immune Checkpoint Inhibitors Increase; to Maximize Value through Combination
March 27, 2015
-
Most Global Products on Track to Clear Their FY2014 Sales Forecasts; Abilify Posting Sales of 650 Billion Yen
March 16, 2015
-
Will SGLT-2 Inhibitors Catch On? Breakout Will Require Accumulation of Data
February 25, 2015
-
Chugai Aims to Surpass 200 Billion Yen in Its Domestic Oncology Sales in 2015
February 13, 2015
-
EFPIA Predicts Growth in Ethical Drug Market to Just 10 Trillion Yen in 2025
February 6, 2015
ページ
With a tumultuous year heading towards a close, let us share the 10 most-read stories on PHARMA JAPAN in 2020. With 2020 being a biennial drug price revision year, our global readers apparently had their eyes riveted on which products…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
As we navigate the lingering effects of the global pandemic, one thing is unmistakably clear - change is here. We’ve changed, and so have our companies. The entire workplace has transformed, but it’s not always a change for the better.…